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Abstract. The current concepts of blood coagulation changes in the pathogenesis 
of acute mountain sickness (AMS), high altitude pulmonary oedema (HAPO), 
high altitudepulmonary hypertension (HAPH) and chronic mountain sickness 
(CMS) which aflict the inductees and residents at  high altitude have been 
reviewed. Hypercoagulable state which is more marked during the first few days 
of exposure is countered by enhanced fibrinolytic activity and accelerated cell 
mediated immunity. Magnesium levels are increased in normal residents at 
high altitudes and may be responsible for enhancing fibrinolytic activity and 
accelerating immune responses. Magnesium levels are significantly reduced in 
HAPO patients. Judicious use of furosemide in lower dosage is still the mainstay 
of treatment of HAPO and AMS. 
1. Introduction 
The interest in high altitude physiology has increased immensely for a variety of ' 
reasons which include defence of our country, wealth of mineral reserves, health 
resorts, instinct for adventure, recreation and natural beauty of mountains. A large 
number of people therefore live at high altitudes or go to high altitude. Solar radia- 
tion, hypoxia, hypobaric pressure, and cold are the primary factors which adversely 
affect the physiological responses in7 man at high altitude. Main illnesses which 
afflict inductees and residents at high altitude are acute mountain sickness (AMS), 
high altitude pulmonary oedema (HAPO), high altitude pulmonary hypertension 
(HAPH) and recently discovered chronic mountain sickness (CMS) in the Himalayas. 
Our experience of these illnesses dates back to the days of the Chinese aggression on 
our Northern borders in 1962. Alarge amount of relevant information has been 
collected, since then on the clinical and pathophysiological aspects of the above 
disorders1-g. Pathogenesis of these disorders is far from clear. The aim of the 
present communication is to review the current concepts of blood coagulation changes 
in their pathogenesis. 
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2. Haemostasis at High Altitude 
First few days of recent arrivals at high altitude are very critical. During these days 
important adaptative changes take place in them, failure of which may initiate adverse 
pathophysiology resulting in development of acute mountain sickness and high alti- 
tude pulmonary oedema. These are fast developing acute illnesses which if left 
untreated could prove fatal. In fulminating cases, commonly precipitated by exercise, 
the whole course from the onset to death may be less than 30 minutes. There is a 
time lag from 6 to 96 hours between arrival at high altitude and onset of both the 
disorders1-6. However, majority of HAP0 cases occur within the flrst 4 days and the 
chances of its developing become remote after 7 to 14 days. 
It is in this context that changes in blood coagulation at high altitude within first 
few days of arrival become revealing. 
On immediate arrival or within 24 hours at high altitude there is a tendency to- 
wards hypercoagulation associated with an increase in platelet count, factors X and 
XII, and thrombotest activity. It is also reflected by shorter prothrombin time, 
bleeding time, clotting time in glass and in silicone, and stypven time. Clot retrac- 
tion is impaired. This state of hypercoagulation is countered by a compensatory rise 
in fibrinolytic activity evident by reduction of clot lysis time, plasma fibrinogen, and 
factor VIII"5. 
On day 3, factor V decreases, bleeding time and stypven time are further shorten- 
ed, and factor VIII shows a rise. On day 7, a progressive rise occurs in factors 
V, VIII, X and XII, thrombotest activity, platelet count and platelet factor 3 (PF-3). 
Clotting time in glass and silicone, prothrombin time, and stypven time show further 
shortening. 
On day 14, haematocrit rises and of all the parameters, factors V and X, and clot 
retraction return to normal. Throughout the fortnight, factor XI1 remains high, clot 
lysis time shot t, thrombin clotting time prolonged, and platelet adhesiveness remains 
within normal range. PF-3 availability remains high in the later half of the fortnight 
only. No significant change occurs in calcium time throughout the fortnight3'=. 
A delicate balance seems to exist between the coagulant and fibrinolytic forces. 
Based on the numerical score, in this study, the state of hypercoagulation, on arrival 
at high altitude (3692 m), has been expressed as + 11 on day 1, + 9 on day 3, + 28 
on day 7, and + 17 on day 14 in recent arrivals. From the above account it is 
evident that immediately on arrival at high altitude there is a tendency towards a 
hypercoagulation state, however, it is counteracted by increase of fibrinolytic activity 
in the normal c i r c ~ m s t a n c e ~ ~ ~ ~ ~ ~ ~ 0 .  
This hypercoagulation state persists throughout the early fortnight after arrival 
at high altitude and then starts regressing. What seems to be an adaptative compro- 
mise during continuous stay at high altitude, there is further regression of the 
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coagulant state. It is indicated by persistent short clot lysis time accompanied with 
prolongation of bleeding time, clotting time in silicone, prothrombin time, stypven 
time, calcium time, and thrombin clotting time. Thrombotest activity is reduced. 
Platelet adhesiveness, PF-3, factors V, V[lI and XI1 and clot retraction are restored to 
normal. However, the reduction in hypercoagulation on prolonged stay at  high 
altitude is partly checked by significant increase in plasma fibrin~gen~;~.  
Our findings that acute expowre to high altitude brings about a state of hyper- 
coagulability in man are in conformity with those of Genton and his associates in 
their animal studiesl1. They recorded significant reduction in platelet half life and 
fibrinogen half life in calves exposed to high altitude (4310 m) for 10 days. Plasmi- 
nogen showed a rapid decrease in animals but fibrinolytic activity was not found to 
be altered. Our observations on platelet numbers are at variance with those of Gray 
et all2 and Chatterji et alls who recorded fall in platelet counts in their subjects after 
2 days exposure to high altitude, however, the latter authors showed a concomitant 
decrease in platelet aggregation and explained that their results could be affected by 
the presence of increased fibrinogen degradation productsl4*'S due to increased fibrino- 
lytic activity at high altitude and also by increased amount of 2, 3-diphosphoglycerate 
(2, 3 DPG), a known physiological inhibitor of platelet aggregation1', which usually 
increased on exposure to hypoxia17. Fall in plasma fibrinogen and factor VIII were 
observed by Maher and associates17 on second day of high altitude exposure (simulat- 
ed altitude 4400 m) but no alterations were found in platelet count, prothrombin 
time, thrombin time and PF-3, though the partial thromboplastin time was shortened 
in this study. 
It can be concluded that a transient state of hypercoagulability is induced on acute 
exposure to high altitude. Increased amount of coagulation factors and increased 
platelet adhesiveness/aggregation may lead to sequestration of young and adhesive 
platelets, from circulation, in the pulmonary vascular bed12. But the compensatory 
rise in fibrinolytic activity is a fortunate sign to counteract this tendency. After a 
fortnight sojourn at high altitude, the initial state of hypercoagulability is almost 
overcome as a result of persistent increase of fibrinolytic activity which prevails 
throughout the rest of stay at high altitudelo. Women at high altitude are better dis- 
posed in this respect since their status of fibrinolytic activity is of a higher magnitude 
than that of men. In our experience, the adverse changes in blood coagulation 
induced by exposure to high altitude revert to normal on eescent to plains. Platelet 
adhesiveness, clot lysis time, factor V and VIII, stypven time and thrombin clotting 
time return to normal within one week. PF-3, fibrinogen, thrombotest activity, pro- 
thrombin time and calcium time are restored to normal values within one to three 
weeks of arrival at sea level4. 
3. Acute Mountain Sickness 
Acute mountain sickness is the most common manifestation encountered on arrival a t  
high altitude without acclimatization and is characterized by headache, nausea, vomi- 
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ting, insomnia and lassitude in milder form. In its severe form it may be presented 
with some neurological features which may include irritability, drowsiness, hallucina- 
tions, ataxia, stupor, fits, coma and paralysis etc or it may form a part of high altitude 
pulmonary oedema accompaniedLwith progressive dyspnea, tachypnea at rest, blood 
stained and frothy sputum and moist basal crepitations or widespread rales invariably 
involving both lungs. The pathogenesis of AMS is largely obscure. Rapid ascent, 
exercise, and anti-diuresis are the common precipitating factors for both AMS and 
HAPO. These symptoms occur over a period of 6 hours to 5 days when lowlanders 
ascend to high a l t i t ~ d e s ~ ' 1 ~ ' ~ ~ .  The symptom-complex of AMS is readily relieved by 
diuretic therapy. The general consensus is that there is an initial hypersecretion of 
adrenal corticosteroids, anti-diuretic hormone and aldosterone with renal retention of 
water and electrolytes and a marked intracellular shift of fluidBq20-22. Recently 
Rennie has summarised that both severity and incidence of AMS are proportional to 
speed of ascent and degree of exertion and inversely related to age23. In his subjects 
rapid weight .gain, associated with flat neck veins and high urine osmolality, is a reflec- 
tion of body water retention. The above mechanisms are alleged to operate con- 
comitantly with effects of hypoxia and cause peripheral venous constriction leading 
to increased pulmonary blood volume, congestion and/or frank pulmonary oedema. 
This in turn results in oliguria and development of cerebral oedema which causes 
headache and other neurological disorders. The elevation of CSF pressure results in 
papilloedema and retinal haem~rrhages~ ' -~~.  Meehan and Zavala attribute retinal 
hemorrhages to the frequent Valsalva manoeuveres, increase in venous pressure and ' 
its transmission to dilated ~api l lar ies~~.  Alternately, the role of the sympatho-adrenal 
system and increased secretion of catecholamines persistently in the symptomatic 
group of AMS has been stressed to result in intracellular shift of fluid2*. Increased levels 
of circulating catecholamines have been implicated in affecting platelets adversely 
resulting in increased platelet adhesion, platelet aggregation and formation of platelet 
and fibrin thrombi within the pulmonary arteries, venules and capillaries in cases of 
high altitude pulmonary oedemas. More recently Maher and associatesg0 have observ- 
ed multiple coagulation abnormalities in a group of subjects who developed symptoms 
of AMS when subjected to a simulated altitude (4400 m) exposure from 1 to 48 hours. 
, 
The symptoms in the exposed group were associated with significantly shortened 
partial thromboplastin time, and fall in plasma fibrinogen and factor VIII levels after 
one hour of high altitude exposure. While partial thromboplastin time remained 
reduced throughout the study, plasma fibrinogen and factor VIII were elevated after 
24 and 48 hours of the exposure, more or less returning to pre-exposure levels. Some 
of the subjects showed also an evidence of transient presence of late fibrinogen degra- 
dation products suggesting activation of secondary fibrinolysis, a compensatory pheno- 
menon to counter hypercoagulation state. A concomitant rise in 2, 3-DPG seemed 
to have masked the abnormal platelet activity in this studya0. However, some workers 
have noted increase in platelet adhesiveness in the symptomatic subjects who were 
air-lifted to an altitude of 3658 m, the increase was maximum on the tenth day of 
the exposures1. The alterations in the haemodynamics on arrival at high altitude do 
play their part in the development of AMS6 but the role of blood hyperviscosity and 
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hypercoagulability, and platelet aggregation is largely unknown. However, the acute 
mountain sickness, benign or malignant, involving brain and lungs, is the variant of 
the same diseased process and undoubtedly there is increasing body of evidence that 
li, thrombosis at least is an important and possibly the primary event in the pathogenesis 
of acute high-altitude illnesses/variantsS2. Simultaneous appearance of symptom- 
complex of AMS and the abnormal blood coagulation changes on acute exposure to 
high altitude strongly suggests the involvement of coagulopathy in the aetiopatho- 
genesis of this disorder. If these observations are further confirmed, then a rational 
therapy with anticoagulants and anti-platelet aggregating drugs could be evolved for 
prophylaxis and treatment of this syndrome. Till then prevention 01 acute mountain 
sickness can be best achieved by gradual ascent and avoidance of strenuous exertion 
by trekkers at the high altitude. 
4. High Altitude Pulmonary Oedema 
High altitude pulmonary oedema is a noncardiogenic pulmonary oedemas3 which 
develops on arrival at high altitude between 6 and 96 hours. Majority of cases occur 
within first four days and the chances of its developing become remote after 7 to 14 
Adolescents and children, unmindful of exerting unnecessarily, are more prone to 
develop HAP0 and reinductees including high altitude natives who reascend after a 
short stay, even one day in some cases, at lower altitude are at greater r i ~ k ~ j - ~ ~ .  1n 
haemodynamic studies of patients of HAPO, the pulmonary blood volume is found to 
be increased and remains so from 3 to 24 weeks after evacuation to sea levela4. There 
is no evidence of left ventricular failure. The left atrial and the pulmonary venous 
pressures are normal. Electrocardiac findings reveal right atrial strain or right vent- 
ricular overloads9 and a normal heart size40. Radiologically patchy densities noted 
in high altitude pulmonary oedema are identical in distribution and intensity to the 
increased areas of blood Necropsy studies reveal widespread pulmonary 
oedema, severe capillary congestion, and enormous distension of the pulmonary blood 
vessels upto capillaries, extensive plugging of alveolar capillaries with sludged red 
blood cells, fibrinous and protein-rich exudate in the alveoli and hyaline membrane 
lining these, features similar to those seen in patients with respiratory distress synd- 
rome. Also multiple fibrin thrombi were observed not only in pulmonary capillary 
bed but in the kidney, plugging the glomerular and peritubular arteries, and also in 
the sinusoids in livers4. Such dilatation of preterminal arterioles and vascular obstruc- 
tion by thrombi containing platelet aggregates, white and red blood cells, and fibrin 
strands in lung fields have been described by a number of w o ~ k e r s ~ l - ~ ~ .  Besides the 
above lesions, infection and atelectasis in lung and haemorrhages in the brain have 
also been reported in mountaineers who suffered from acute mountain i l l n e s ~ ~ ~ - * ~ .  
Some degree of pulmonary hypertension appears to be inevitable at high altitudes 
and it exists invariably as a part of high altitude pulmonary oedema. The persistence 
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of pulmonary hypertension for weeks after the pulmonary oedema has subsided is an 
indication that the changes induced in the pulmonary circulation are not entirely 
functional. The sludging of cells and the fibrin thrombi in the alveolar capillaries 
and venules add an organic element to the picture. These findings suggest that 
exposure to hypoxic stress causes a breakdown of the fibrinolytic enzyme system, and 
the equilibrium between fibrin formation and dissolution is upsetdB. These observa- 
tions prompted us to study the blood coagulation parameters in the acute stage of 
illness in HAPO patients on the spot (3692 m). As described earlier, within first few 
days at high altitude, a state of hypercoagulability in recent arrivals runs parallel with 
the incidence of occurrence of HAP08*5949*50. Blood coagulation studies carried out 
in patients of HAPO and compared with suitable controls reveal a causal relationship 
between changes in fibrinolytic activity, blood coagulation factors, platelet functions, 
and formation of thrombi in the pulmonary circulation. The following changes 
have been observed at the very outset of the illness. Fibrinolytic activity is reduced. 
Plasma fibrinogen and factor VIII are increased. Factor XI1 is decreased. Platelet 
adhesiveness and PF-3 are significantly increased and are associated with fall in plate- 
lets. Clot retraction is markedly impaired. Less significant changes are noted in 
factor V, factor X, and the haematocrit which are increased; thrombin clotting 
times are r e d u ~ e d ~ * ~ * ~ ~ .  Electrophoretic mobility of platelets is r e d ~ c e d ~ ' ~ ~ .  Both 
arterial and venous adenosine-diphosphate (ADP) levels are significantly low com- 
pared to controls and there is evidence of sequestration of ADP and platelets in the 
pulmonary bed in In light microscopy of peripheral blood smears of 
HAPO patients, larger and young adhesive platelets are found in aggregates in greater 
The electronmicroscopic studies of platelets of HAPO patients reveal 
that the integrity of plasma membrane, capacity for pseudopodia formation, and the 
ability of degranulation are intact, showing thereby that platelets from the patients 
are active both structually and functionally (Fig. l)3*5'5a. It is evident that in patients 
of high altitude pulmonary oedema platelet factor 3 and the substrate for thrombin 
generation and fibrin formation are provided abundantly. PF-3 provides an active 
catalytic surface for the interaction of plasma coagulation factors leading to thrombin 
generation. The resulting consolidation of platelets leads to their degranulation 
with the release of more PF-3 and ADP and further fibrin formation. Increased 
platelet factor 3 and platelet adhesiveness in the patients promote the above chain of 
events resulting in formation of platelet and fibrin thrombi in lungs at the capillary 
and venular level. This impedes the pulmonary blood flow and results in overper- 
fusion and exudation of protein rich fluid and even cells. This process results in 
patchy oederna formation in lungs. Such scattered thrombotic occlusions in cerebral 
microvasculature might be expected to result in cerebral oedema with consequent 
compression and symptom-complex of AMS. Papilloedema and retinal haemorrhages 
can also be, perhaps, accounted for by such thrombotic process in tetinal vessels. 
No alteration in fibrinolytic activity has been reported so far in patients of AMS 
but a state of hypercoagulability and evidence of coagulopathy have been the early 
feature in this sickness. In HAPO, however, higher plasma fibrinogen levels associ- 
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Fieure 1. Electronmicrograph of platelets from patients of high altitude pulmo- 
nary oedema, stained with uranyl acetate and lead citrate, X 20,000. 
Pseudopodia, dense granules and glycogen particles are seen. 
ated with reduced fibrinolytic activity appear to be character is ti^^^. In the event of 
breakdown of the fibrinolytic system in this disease the pendulum swings to coagula- 
tion acceleration and proves fatal unless treated energetically with appropriate measures 
and drugs to clear pulmonary congestion and remove impediments to blood flow in 
the microcirculation in lungs and other affected organs1*50'5S*54. 
An important feature, in HAPO patients, is the markedr ise in immunoglobulins 
IgG, IgA and IgMS*6952155*s6. IgG and IgM get adsorbed on the surface of platelets, 
alter their mobility, increase their aggregation, and enhance the release of ADP which 
in turn promotes the availability of PF-3, the latter amplifies further the coagulation 
process. Recently we have found that a diachotomy of immune responses exists in 
patients of HAP057n58. Immun~globulins are increased on one hand and on the 
other, the cell mediated immunity (CMI) is impaired. This derangement of CMI 
helps to promote persistence of immune complexes, activated clotting factors, and end 
products of blood coagulation and thereby accentuates intravascular coagulation in 
this disorder. Impairement of CMI in HAPO coincides with diminished fibrino- 
lytic activity, when fibrinolytic activity improves the CMI is also r e s t ~ r e d s ~ ' ~ ~ .  Our
most recent and interesting observation is that both erythrocyte and leucocyte 
magnesium contents are significantly higher in normal and healthy residents at high 
altitude but are reduced significantly in patients of high altitude pulmonary 
~ e d e m a ~ ~ ~ ~ l  (Fig. 2). The role of magnesium on immune response and blood 
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coagulation is well documented. Magnesium deficiency is associated with decreased 
synthesis of imrnunog l~bu l ins~~ '~~  and depressed CMIs4. Magnesium exerts a favour- 
able effect on blood coagulation which it reduces by its vasodilatory action, its stabi- 
lisation of fibrinogen and platelets, and by its stimulation of fibrinoly~is6~'~~. There- 
fore, low magnesium levels in patients of HAPO have a relevance since these are 
related to diminished fibrinolytic activity and impaired CMI in them. 
WAGNESIUM LEVELS AT HIGH ALTITUDE 
2 . 5 1  RBC 
Figure 2. Erythrocyte and leucocyte magnesium levels in mMol/L in sea level 
residents (SL), high altitude residents (HA-N), and patients of high altitude 
pulmonary oedem:! (HAPO). 
High altitude provides both enhanced fibrinolytic activity and accelerated immune 
responses. Possibly it is because of this higher fibrinolytic and immune-potential 
that malignancy is scarce at high altitude. Studies of populations in the Andes, the 
Himalayas and the United States have shown a low or less common incidence of . 
myocardial infarction, ischaemic heart disease, and arteriosclerotic heart disease 
m ~ r t a l i t y ~ " ~ ~ .  
The inter-relationship between the abnormalities in fibrinolysis, blood coagulation 
factors and platelet functions described above in the pathogenesis of high altitude 
pulmonary oedema is,depicted in Fig. 3. 
5. High Altitude Pulmonary Hypertension 
High altitude pulmonary hypertension either forms a part of high altitude pulmonary 
oedemal and is acute at the onset, or occurs after a long stay at high altitude in  
temporary residents2 and permanent  dweller^^^-^^ as a protracted course. In the 
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Figure 3. Interrelationship of mechanisms in the orlgin of adverse changes in 
fibrinolytic activity, blood coagulation factors, platelet functions, and immune 
responses predisposing to intravascular coagulation in high altitude pulinonary 
oedema. 
latter situation 5 to 42 months elapse before it makes its appearance. The hyperten- 
sion either continues to persist on arrival at sea level or, if it subsides, it reappears 
within 2 to 3 weeks of individual's return to high altitude7'. The hall-mark of clinical 
pathologyis characterised by dyspnea on effort, chest pain, accentuated or split 
second pulmonary sound, clockwise rotation, and prominent pulmonary artery on 
X-ray examination. When right ventricular failure supervenes, the juglar venous 
pressure is raised, liver becomes tender and palpable, and ascites, oedema and cyano. 
sis follow. All these consequences, of pulmonary hypertension and right ventricular 
hypertrophy, appear to result from progressively increasing pulmonary vasoconstric- 
tion and muscularisation of pulmonary arterial bed resulting in increased pulmonary 
vascular resi~tance7~'7~ in subjects exposed to hypoxia of high altitude, the hypoxia 
may be intermittent or continuous. 
Only partial reversibility of pulmonary hypertension, as a result of oxygen inhala- 
tion and evacuation to sea level, and its rapid return on ascent to high altitude 
370 I S Chohan 
prompt us to believe that it may have an organic basis. Association of adverse coagu- 
lation changes and necropsy evidence of widespread fibrin thrombi in the alveolar 
capillaries and branches of the pulmonary arteries and other organs in patients of 
high altitude pulmonary hypertension confirms OUI do~bts*-~'~~76. Our suitably con- 
trol-matched study reveals that those who do not develop pulmonary hypertension at 
high altitude only exhibit higher plasma fibrinogen levels and fibrinolytic activity, but 
those who develop HAPH show lower plasma fibrinogen concentration despite high 
fibrinolytic activity, indicating that this may not be adequate to counter the intensity 
of the coagulation forces in patients in whom fibrinogen is being constantly depleted 
by deposition in the pulmonary vascular bed. The coagulation process in the affected 
subjects is facilitated by a significant increase in platelet adhesiveness, platelet factor 
3, factors V and VIII. Factor XI1 is not generally increased in patients and it is 
recovered only on return to sea level, thereby indicating that the Hageman factor- 
dependent pathway of fibrinolysis remains insufficiently responsive in them. Lowering 
of both venous and arterial levels of ADP in patients of HAPB is a further proof of 
excessive utilisation of ADP resulting in platelet sequestration and fibrin deposition 
in pulmonary v a s c ~ l a t u r e ~ ' ~ * ~ ~ .  
Electrophoretic mobility of platelets is also reduced in HAPH, like in HAPO, and 
is related to high plasma fibrinogen and clotting factors in these disorders, and increas- 
ed immunoglobulins in HAP08-5s51*52. 
Electronmicroscopic studies of platelets from high altitude pulmonary hypertension 
patients do not reveal any gross abnormalities. The membranous and cytoplasmic 
constituents are abundant and capacity of pseudopodia formation and degranulation 
is adtquate (Fig. 4). 
In both high altitude pulmonary oedema and high altitude pulmonary hyperten- 
sion, the abnormal state of blood coagulation is attended with increased platelet 
adhesiveness, platelet factor 3, factors V, VIII and X, and the haematocrit values. 
The outstanding difference between the two is in the fibrinolytic activity which is 
reduced in the former but remains persistently increased in the latter8. 
6. Chronic Mountain Sickness 
Individuals, suffering from chronic mountain sickness or Monge's disease have 
been found to have a much higher degree of pulmonary hypertension. Chronic 
mountain sickness-Phobrang type-has a recent history, in the Western Himalayas at 
vulnerable altitude of approximately 14,000 feet (4267 m)7797a. The corresponding 
altitude for CMS to develop is 9,840 feet (3000 m) in the Peruvian Andes79. Most 
patients are young between 24 and 53 years of age. It runs a protracted course and 
takes 8 to 25 months to appear in its florid plethora of the syndrome of alveolar 
hypoventilation accompanied with symptoms of pulmonary hypertension, right ventri- 
cular hypertrophy, and consequences of chronic hypoxaemia. Besides the higher 
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Figure 4. Electronmicrograph of platelets from patients of high altitude 
pulmonary hypertension, stained with uranyl acetate and lead citrate. X 10,000. 
Platelet plasma membrane is intact. Some platelets show degradation, close 
clumping of platelets does not permit visualisation of pseudopodia. 
haemoglobin and haematocrit, the CMS of 'Phobrang type' has an added element of 
renal protein Unique clinical features drawing immediate attention consist of: 
intensely suffused conjunctivae with swelling of eyelids, cyanosed and congested buccal 
mucosa, magenta coloured and cyanosed tongue with or without sublingual haemorr- 
hages, red palms and soles with cyanosed tips of fingers and toes, clubbing and break- 
ing of finger nails with or without splinter haemorrhages, cyanosed earlobes and 
pinnae, petechial haemorrhages over legs, pedal oedema, and engorged neck veins. 
X-Ray chest shows prominent pulmonary conus, increased hilar vascular markings 
and diminished aeration of lung fields and evidence of right ventricular enlargement. 
Electrocardiography shows all the signs of right ventricular strain and overload and 
an accentuated degree of right AQRS deviation which could be of the order of 
+ 152' to + 158'. Systemic hypertension may also be exaggerated in these patients. 
We carried out some blood coagulation parameters in six patients presented to us at 
an altitude of 3692 m in their florid state. Compared to suitable high altitude con- 
trols, patients have significantly increased plasma fibrinogen (400.1 & 37.1 mg/dl), 
haematocrit (74.3 -f: 3. I%), and haemoglobin (23.1 & 2.6 g/dl); significant decrease 
in activated partial thromboplastin time (27.1 * 5.2 sec, compared to normal 35 to 50 
sec) and platelet numbers (177.8 f 10.9 thousand per cmm, compared to normal 
197.4 * 19.3); and significantly reduced euglobulin lysis time (ELT 165 f 75 min, 
compared to normal 399 * 48) Erythrocyte sedimentation rate is reduced to 
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3-5 mm. There is no change in the total and differential leucocyte counts. Altera- 
tions in fibrinogen, activated partial thromboplastin time, platelets, haematocrit, 
haemoglobin and ESR indicate a trend towards hypercoagulable state in patients of 
chronic mountain sickness. However, increase in fibrinolytic activity in them, 
indicated by short euglobulin !ysis time, tends to counteract this trend. A very 
characteristic feature of CMS patients in the presentation of their peripheral 
blood smear. The hyperchromatic and large RBCs form a mosaic pattern with little 
plasmatic matrix and seem to strangulate the WBCs which appear distorted in shape, 
some are tailed but there are no other abnormalities. Large and young platelets 
lie scattered singly or in batches and seem to be strangulated in the mosaic. Rouleaux 
formation by RBCs is also common. 
Another redeeming feature in patients of CMS is presence of accentuated cell 
mediated immunity (CMI) indicated by 'spontaneous flare' and 4 + DNCB-reaction 
in thema1, unlike patients of high altitude pulmonary oedema who exhibit impaired 
CMI in the acute stage of i l l n e s ~ ~ ~ - ~ ~ .  Accentuated CMI and fibrinolytic activity, 
perhaps, account for the protracted course of CMS. 
The pathophysiology of CMS emanates from restricted ventilatory response to 
hypoxaemia and/or hypercapnoea resulting in diminished arterial oxygen saturation 
so that polycythaemia and cyanosis develop in this syndr~me~O-~~.  Functional arte- 
riolar constriction at  the precapillary level in the pulmonary vascular bed leading to 
sustained rise of pulmonary arterial pressure and its subsequent consequences is 
reversible on descent to sea levels5. The role of prostaglandins in development of 
pulmonary hypertension is largely controversial as acetylsalicylic acid fails to prevent 
advtrse changes in blood coagulation parameterss6 and pulmonary hypertension in 
the cattle exposed to simulated altitude of 4,500 m. Sleep hypoxaemia, during sleep 
at high altitude, has also been suggested as the physiological basis of Monge's 
diseasee7. Few necropsy reports are described illustrating the pathological features 
of this diseasesO'ss'ss. These studies compiled by Heath and Williamsg0 emphasize, 
the thickening of peripheral pulmonary arteries and muscularization of pulmonary 
arterioles, the whole basis of development of pulmonary hypertension resulting from 
alveolar hypoxia at the high altitudeg0. Arias-Stella and colleagues have also report- 
ed presence of fresh and partially organized thrombi in the pulmonary arteries and 
arterioles in their material together with occurrence of colloid goitre and hyperplasia 
of the zona glomerulosa of the adrenal cortexs0. Our above study, reporting altera- 
tion in blood coagulation parameters in CMS (Phobrang type), may be relevant in 
this context. The degree of fibrinolytic activity observed in CMS may not be adequ- 
ate to deal with fibrin deposition in the pulmonary microcirculation and this process 
may gradually lead to occlusion of the alveolar capillaries, reduction of oxygen 
exchanging capacity, and production of hypoxaemia. This, however, is only a postu- 
lation which needs confirmation. 
Oxygen administration has no place in" the therapy of CMS. Other forms of 
therapy recommended are <evacuation to lower levels, phlebotomy, steroids, and a 
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ventilatory stimulant-medroxyprogesterone acetate (MPA)79'96*9'. A combined 
therapy consisting of lowering altitude, acetylsalicylic acid, acetazolamide, and deep- 
breathing yogic exercise was used in the treatment of CMS in the Himalayas in a 
recent study with satisfying r e s ~ l t s ~ ~ ' ~ 8 .  It may be of passing interest that recently 
yoga has been shown to induce a state of hypocoagulability in mang2. Yoga promotes 
fibrinolytic activity with a concomitant fall in plasma fibrinogen; prolongs activated 
partial thromboplastin time and platelet aggregation time; and spares platelet consump- 
tion. Learning and practice of yoga may be prescribed as a part of training, advan- 
tageously, for the mountain trekkers and soldiers before their induction to the high 
altitudes. 
7. Discussion 
There is an increasing body of evidence that the above disorders of high altitude, 
occurring in mountain climbers and dwellers, are the variants of the same primary 
event resulting from the lack of acclimatization and adaptation to these environments. 
There is a good reason to believe that hypercoagulation and thrombotic process play 
an important and possibly a primary role in their development and progression from 
a mild state to a severe one. Admittedly, there is a clear need for their early recogni- 
tion and prevention and appropriate treatment to check avoidable m i ~ h a p ~ ~ - ~ ~ .  Acute 
mountain sickness of mild intensity, benign AMS, is a self limiting illness and the 
early phase of severe symptoms subside within 2 to 5 days but complete recovery 
takes few weeks to months. Those who have cerebral and pulmonary elements need 
energetic treatment. Those who fail to adapt within 6 months have to be evacuated 
to plains" In contrast to symptoms of hyperventilation and tachycardia which occur 
on immediate arrival and respond to oxygen inhalation, the symptom-complex of 
AMS is not readily relieved by oxygen therapy. Though oxygen is essential to relieve 
dyspnoea during the acute stage of HAPO, induced diuresis is the mainstay of treat- 
ment of both AMS and HAPO. Diuretics, furosemide in particular, have been 
effectively used to reverse the fluid retenti0n6'~O. Furosemide has been used in the 
dosage of 40-80 rng every 12 hours for 2 days and with this regimen, symptoms and 
signs of AMS are relieved within 6 to 48 hours. In severe cases of AMS especially 
with pulmonary and cerebral elements, morphine 15 mg added with the first dose of 
furosemide has been found very effective as it brings about more effective diuresis, 
reduces pulmonary blood volume, alleviates anxiety and induces mild sleep, all these 
factors promote rapid recovery. In more severe cases with neurological involvement 
betamethasone combined with furosemide has proved life saving6. Recently, dexame- 
thasone, a potent synthetic glucocorticoid with negligible mineralocorticoid activity, 
which has been effective in the management of cerebral oedema of diverse origing6, 
has been used with significant success in reduction of AMS symptom score in subjects 
exposed to simulated altitude of 4570 mS7. Furosemide, though found effective as a 
prophylactic measure against development of AMS, however, used in large dosage of 
80 to 200 mg given orally may result in copious diuresis with massive potassium loss 
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and hence lead to overdehydration, cramps, and non-relief of headache in ati already 
dehydrated individual in the high altitude environments where water is not readily 
available to replace the loss. Under the above circumstances furosemide administer- 
ed in large doses may prove inconvenient and hazardous, hence it has not found 
favour with some authors and rightly We have recently started using a lower 
dosage regimen of 20 mg furosemide every 12 hohrs to treat HAP0 with no less 
success and without any side e f f e c t ~ ~ 0 * ~ ~  and with other good reasons described below. 
Acetazolamide, a less potent diuretic, is the only other drug which has been advo- 
cated as a prophylactic against AMS1s*19*9s-102. However, it has been partly 
e f f e c t i ~ e ~ ~ * ~ 2 ~ ~ ~ , ~ ~ ~ .  The exact mechanism by which the acetazolamide is efficacious is 
unknown but it is known to enhance8 excretion of bicarbonate, increa~e ventilation, 
and thereby reduce arterial desaturationlOs. Acetazolamide no doubt counters respi- 
ratory alkalosis but produces acidosis which could be a disadvantage as acidosis 
predisposes to coagulation. Acetazolamide, in 250 mg oral doses, may be prescribed 
four times daily for two days before ascent and for four days after. Some climbers 
have reported marked acute mountain sickness on discontinuation of the drug during 
ascentlo4. 
Aspirin has also been used to relieve headache, a component of AMS symptom- 
complex6'105. Recently spironolactone, an' antialdosterone, has been used as a succ- 
essful prophylactic against AMSlo5-108, although subjects with acute mountain sick- 
ness have lower aldosterone levels than subjects less affectedlo7. It remains to be seen 
as to what extent aldosterone is responsible to cause AMS. Othef studies have 
demonstrated that treatment with digitalis and isoproterenol have not been 
benefi~ial~~. 
8. Why Furosemide and Allied Drugs ? 
Furosemide, apart from inducing rapid diuresis and reducing pulmonary blood 
volume, enhances plasma fibrinolytic activity; decreases factors V, VIIT and X, and 
thrombotest activity; increases factor XII; reduces platelet factor 3 and platelet adhe- 
siveness; and improves clot retraction in patients of high altitude pulmonary 
~ e d e r n a ~ ~ ' ~ ~ .  Thus by virtue of its,ability of #eversing adverse changes in fibrinolytic 
activity, blood coagulation factors, and platelet function furosemide removes impedi- 
ments and improves pulmonary blood flow at the capillary and venular level. These 
beneficial effects of furosemide become manifest within 30 minutes and lead to an 
uneventful recovery. Furosemide also exerts an inhibitory effect on primary platelet 
aggregation induced by ADP, both in vitro and in vivo, an inhibitory effect on platelet 
secretion has also been demonstrated by its influence on secretion of 14C-serotonin 
and platelet f a c t o r 4  (PF-4) with small concentration of 50 pMlo9. Since furosemide 
increases the electrophoretic mobility of platelets (our unpublished data), the restora- 
tion of the Hageman factor following furosemide administration6' is responsible for 
this effect. Hageman factor is a sialoglycoprotein which is easily adsorbed on the 
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platelet surface and increases its negative electric charge. The above effects of 
furosemide depend on its vasodilatory activity, cyclic-AMP phosphodiesterase inhibi- 
tory and adenyl cyclase stimulatory capacity, and its activation of the Hageman 
factor-mediated fibrinolytic system as long as the integrity of thz renal parenchyma 
is intact and the diuresis is r n a n i f e ~ t ~ ~ ~ ~ ~ ~ ' ~ ~ ~ .  The net effect of the above mentioned 
mechanisms is increase in cyclic-AMP. The natriuretic effect of furosemide is well 
known to be mediated by prostaglandin E (PGE) induced cyclic-AMP. Cyclic- 
AMP has been demonstrated to inhibit synthesis of prostaglandin endoperoxides 
(PGG,) which is the immediate precursor of thromboxane Az that effects platelet 
aggregation and secretion of human platetets112. Platelet aggregation induced by 
PGG, has been shown to be inhibited by furosemide113, and also the formotion of 
malondialdehyde, an indicator of platelet prostaglandin synthesis, is inhibited by 
furosemide114. Evidently furosemide inhibits the synthesis and antagonises the action 
of prostaglandin G, but selectively promotes the crction of PGE and synthesis of 
cyclic-AMP, the latter promotes in turn inhibition of platelet aggregation and release 
reaction. Aspirin inhibits indiscriminately the synthesis of all prostaglandin endo- 
peroxides by interfering with the action of cyclo-oxygenase enzyme. Furosemide has 
thus the unique property of inhibiting platelet activity and promoting the fibrinolytic 
system. Acetazolamide, aspirin, and spironolactone have not so far been shown to 
induce fibrinolytic effect. Therefore, furosemide has the supremacy over all these 
drugs to combat the propensity of intravascular coagulation in the management of 
AMS and HAPO, preferably in smalle* doses to retain the benefical effect on blood 
coagulation and the attenuated diuretic acti0n~0*~~. Similar results can be achieved 
by using a new synthetic fibrinolytic and anti-platelet agent, piretanide 6 mg adminis- 
tered orally, which is similar in structure and function115 to furosemide. Bumetanide 
is another high-ceiling diuretic, similar in structure and function to furosemide, which 
can be advantageously used in the management of HAP0117-11s. I t  is equipotent 
with furosemide at a fortieth the molar dose. The effective dose is 1 mg intravenously 
and 2 mg orally daily. It has been used effectively in climbers in the Hindu Kush 
range of Afghanistan (7450 m)lZ0. It induces a peak diuresis 1-2 hours after an oral 
dose and its action is complete within 4-6 hours. At the moment, bumetanide is 
slightly cheaper than furosemide and it may prove an effective alternative on the 
rare occasion when furosemide fails. Houston & Dickinsonlzl advocate the use of 
furosemide to combat the cerebral oedema of AMS and also reinforce the treatment 
with rapid injection of hyperosmolar solutions of urea, 50 per cent saline, mannitol 
or 50 per cent sucrose. 
Furosemide, like bumetanide, is known to be bound to plasma proteins122 and it 
may be slowly released from its stores in liver and kidneyslZ3 to maintain its continu- 
ous effect on platelet and fibrinolytic system. The protective effects of furosemide to 
prevent development of acute renal tubular necrosis and acute renal failure by neph- 
rotoxic drugs in animals124 and to prevent crisis of eclampsia in clinical condition of 
toxaemia in pregnancytz5 can be attributed to beneficial properties of this drug. The 
improvement of blood flow in transplanted kidneys by using a furosemide-perfusate 
has been achievedI26 by influencing platelet thrombi and fibrinolytic activity which are 
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adversely affected and involved in rejection crisis. More recently, with the use of 20 mg 
furosemide (I V), an efficient excretion fraction and glomerular filtration have been 
obtained in the allotransplanted kidney patients1:'. Lately, Sniderman and colleagues128 
have treated 28 preterm infants with chronic lung disease due to bronchopulmonary 
dysplasia/chronic pulmonary insufficiency with 1-2 mg/kg furosemide Qid. Of these 
20 infants improved significantly and 12 exhibited deterioration on discontinuation of 
furosemide. These beneficial effects of furosemide may be presumed by improving 
the microcirculation of the organs as a result of enhancement of fibrinolytic system 
and prevention of adverse platelet activation. Furosemide and allied drugs seem to 
have a rightful place in the treatment of diseases where intravascular coagulation is 
involved. 
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